The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

Vaccinology is shifting toward synthetic RNA platforms which allow for rapid, scalable, and
cell-free manufacturing of prophylactic and therapeutic vaccines. The simple development …

Messenger ribonucleic acid (mRNA)-based drugs, notably mRNA vaccines, have been
widely proven as a promising treatment strategy in immune therapeutics. The extraordinary …

T cells directed against mutant neo-epitopes drive cancer immunity. However, spontaneous
immune recognition of mutations is inefficient. We recently introduced the concept of …

Messenger RNA (mRNA)-based therapeutics hold the potential to cause a major revolution
in the pharmaceutical industry because they can be used for precise and individualized …

Messenger RNA (mRNA) has broad potential for application in biological systems. However,
one fundamental limitation to its use is its relatively short half-life in biological systems. Here …

During the COVID-19 pandemic, mRNA (mRNA) vaccines emerged as leading vaccine
candidates in a record time. Nonreplicating mRNA (NRM) and self-amplifying mRNA (SAM) …

Lymphoid organs, in which antigen presenting cells (APCs) are in close proximity to T cells,
are the ideal microenvironment for efficient priming and amplification of T-cell responses …

In the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool
for vaccination. In the following decades, an improved understanding of the mRNA …